Fettweis G, Wagh K, Stavreva D, Jimenez-Panizo A, Kim S, Lion M
bioRxiv. 2024; .
PMID: 39713324
PMC: 11661173.
DOI: 10.1101/2024.12.09.627537.
Zhang J, Tang M, Shang J
Biomolecules. 2024; 14(2).
PMID: 38397426
PMC: 10886696.
DOI: 10.3390/biom14020190.
Meinzinger A, Zsigmond A, Horvath P, Kellenberger A, Parej K, Tallone T
Int J Cell Biol. 2023; 2023:7121512.
PMID: 37941807
PMC: 10630016.
DOI: 10.1155/2023/7121512.
Yao J, Tao Y, Hu Z, Li J, Xue Z, Zhang Y
Front Pharmacol. 2023; 14:1225951.
PMID: 37808197
PMC: 10551544.
DOI: 10.3389/fphar.2023.1225951.
Wu W, LoVerde P
PLoS One. 2023; 18(9):e0286107.
PMID: 37699039
PMC: 10497141.
DOI: 10.1371/journal.pone.0286107.
NRPreTo: A Machine Learning-Based Nuclear Receptor and Subfamily Prediction Tool.
Madugula S, Pandey S, Amalapurapu S, Bozdag S
ACS Omega. 2023; 8(23):20379-20388.
PMID: 37323377
PMC: 10268018.
DOI: 10.1021/acsomega.3c00286.
Spatial definition of the human progesterone receptor-B transcriptional complex.
Yu X, Yi P, Panigrahi A, Lumahan L, Lydon J, Lonard D
iScience. 2022; 25(11):105321.
PMID: 36325049
PMC: 9618773.
DOI: 10.1016/j.isci.2022.105321.
N-Terminal Domain Mediated Regulation of RORα1 Inhibits Invasive Growth in Prostate Cancer.
Park S, Park I, Kim H, Lee J
Int J Mol Sci. 2019; 20(7).
PMID: 30987323
PMC: 6479703.
DOI: 10.3390/ijms20071684.
Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions.
Rodriguez A, Blanchard Z, Maurer K, Gertz J
Horm Cancer. 2019; 10(2-3):51-63.
PMID: 30712080
PMC: 6542701.
DOI: 10.1007/s12672-019-0358-9.
Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue.
Heudobler D, Rechenmacher M, Luke F, Vogelhuber M, Pukrop T, Herr W
Int J Mol Sci. 2018; 19(11).
PMID: 30424016
PMC: 6274845.
DOI: 10.3390/ijms19113540.
Estrogen receptor subcellular localization and cardiometabolism.
Gourdy P, Guillaume M, Fontaine C, Adlanmerini M, Montagner A, Laurell H
Mol Metab. 2018; 15:56-69.
PMID: 29807870
PMC: 6066739.
DOI: 10.1016/j.molmet.2018.05.009.
New Opportunities for Targeting the Androgen Receptor in Prostate Cancer.
Centenera M, Selth L, Ebrahimie E, Butler L, Tilley W
Cold Spring Harb Perspect Med. 2018; 8(12).
PMID: 29530945
PMC: 6280715.
DOI: 10.1101/cshperspect.a030478.
Ligand-Dependent Corepressor (LCoR) Is a Rexinoid-Inhibited Peroxisome Proliferator-Activated Receptor γ-Retinoid X Receptor α Coactivator.
Shalom-Barak T, Liersemann J, Memari B, Flechner L, Devor C, Bernardo T
Mol Cell Biol. 2018; 38(9).
PMID: 29463649
PMC: 5902596.
DOI: 10.1128/MCB.00107-17.
Coumarin: A Natural, Privileged and Versatile Scaffold for Bioactive Compounds.
Stefanachi A, Leonetti F, Pisani L, Catto M, Carotti A
Molecules. 2018; 23(2).
PMID: 29382051
PMC: 6017103.
DOI: 10.3390/molecules23020250.
Nuclear receptors in cancer - uncovering new and evolving roles through genomic analysis.
Dhiman V, Bolt M, White K
Nat Rev Genet. 2017; 19(3):160-174.
PMID: 29279606
DOI: 10.1038/nrg.2017.102.
Discovery at the interface: Toward novel anti-proliferative agents targeting human estrogen receptor/S100 interactions.
Lee D, Asare B, Rajnarayanan R
Cell Cycle. 2016; 15(20):2806-18.
PMID: 27580430
PMC: 5053565.
DOI: 10.1080/15384101.2016.1220460.
Structural determinant for inducing RORgamma specific inverse agonism triggered by a synthetic benzoxazinone ligand.
Marcotte D, Liu Y, Little K, Jones J, Powell N, Wildes C
BMC Struct Biol. 2016; 16(1):7.
PMID: 27246200
PMC: 4888278.
DOI: 10.1186/s12900-016-0059-3.
The optimal corepressor function of nuclear receptor corepressor (NCoR) for peroxisome proliferator-activated receptor γ requires G protein pathway suppressor 2.
Guo C, Li Y, Gow C, Wong M, Zha J, Yan C
J Biol Chem. 2014; 290(6):3666-79.
PMID: 25519902
PMC: 4319032.
DOI: 10.1074/jbc.M114.598797.
NRfamPred: a proteome-scale two level method for prediction of nuclear receptor proteins and their sub-families.
Kumar R, Kumari B, Srivastava A, Kumar M
Sci Rep. 2014; 4:6810.
PMID: 25351274
PMC: 5381360.
DOI: 10.1038/srep06810.
Novel drugs that target the estrogen-related receptor alpha: their therapeutic potential in breast cancer.
May F
Cancer Manag Res. 2014; 6:225-52.
PMID: 24904222
PMC: 4041375.
DOI: 10.2147/CMAR.S35024.